Security Reports > Aerie Pharmaceuticals

Aerie Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report

https://aeriepharma.com  ᛫ 
Last updated July 2, 2020

Aerie Pharmaceuticals Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Aerie Pharmaceuticals is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Aerie Pharmaceuticals

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.


Data Breaches and Security News


Security Report for Aerie Pharmaceuticals

Want a security rating for your organization?

This report shows a preliminary security rating for Aerie Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Aerie Pharmaceuticals's security performance with other companies